Journal of Diagnostics Concepts & Practice ›› 2021, Vol. 20 ›› Issue (05): 507-511.doi: 10.16150/j.1671-2870.2021.05.016
• Review articles • Previous Articles Next Articles
Received:2020-10-01
Online:2021-10-25
Published:2022-06-28
CLC Number:
| 分级 | ISS | R-ISS |
|---|---|---|
| Ⅰ | β2微球蛋白<3.5 mg/L,且白蛋白≥35 g/L | β2微球蛋白<3.5 mg/L,白蛋白≥35 g/L,LDH正常且没有高危细胞遗传学异常 |
| Ⅱ | 排除Ⅰ级和Ⅲ级 | 排除Ⅰ级和Ⅱ级 |
| Ⅲ | β2微球蛋白>5.5 mg/L | β2微球蛋白>5.5 mg/L,或者LDH升高、有高危组细胞遗传学异常 |
| 遗传学异常 | 预后 |
|---|---|
| 三倍体 | 低危 |
| t(11;14) | |
| t(6;14) | |
| -13 | 中危 |
| 1q扩增 | |
| t(4;14) | |
| 17p13- | 高危 |
| t(14;16) | |
| t(14;20) |
| 分组 | 遗传学异常 |
|---|---|
| 高危组 | t(4;14); t(14;16); t(14;20); Del 17p; p53突变; Gain 1q; RISS分期3; High Plasma Cell S-phase; GEP:High risk signature 双打击MM：任何2种高危遗传学异常; 三打击MM：3个或者更多高危遗传学异常 |
| 标危组 | 其他类型,三倍体; t(11;14); t(6;14); |
| [1] |
Wang S, Xu L, Feng J, et al. Prevalence and Incidence of Multiple Myeloma in Urban Area in China: A National Population-Based Analysis[J]. Front Oncol, 2020,9:1513.
doi: 10.3389/fonc.2019.01513 URL |
| [2] |
Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients[J]. Leukemia, 2014,28(5):1122-1128.
doi: 10.1038/leu.2013.313 pmid: 24157580 |
| [3] | Cohen AD. CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update[J]. Am Soc Clin Oncol Educ Book, 2018,38:e6-e15. |
| [4] |
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group[J]. J Clin Oncol, 2015,33(26):2863-2869.
doi: 10.1200/JCO.2015.61.2267 |
| [5] |
Ong SY, de Mel S, Chen YX, et al. Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group[J]. Bone Marrow Transplant, 2016,51(7):933-937.
doi: 10.1038/bmt.2016.43 URL |
| [6] |
Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]Fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study[J]. J Clin Oncol,2017, 35(25):2911-2918.
doi: 10.1200/JCO.2017.72.2975 URL |
| [7] |
Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma[J]. Blood, 2017,130(1):30-34.
doi: 10.1182/blood-2017-03-774422 pmid: 28432222 |
| [8] |
Özkurt ZN, Sucak GT, Akı ŞZ, et al. Early prognostic value of monitoring serum free light chain in patients with multiple myeloma undergoing autologous stem cell transplantation[J]. Cancer Invest, 2017,35(3):195-201.
doi: 10.1080/07357907.2016.1270958 URL |
| [9] | 李璐, 姜华, 傅卫军, 等. 血清游离轻链比值及差值对初诊多发性骨髓瘤患者预后价值的评估与比较[J]. 中华血液学杂志, 2019,40(4):321-326. |
| [10] |
Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report[J]. Cancer Res, 2004,64(4):1546-1558.
pmid: 14989251 |
| [11] |
Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2[J]. Blood, 2011,117(18):4696-700.
doi: 10.1182/blood-2010-10-300970 URL |
| [12] |
Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)[J]. J Clin Oncol, 2010,28(30):4630-4634.
doi: 10.1200/JCO.2010.28.3945 pmid: 20644101 |
| [13] |
Walker BA, Wardell CP, Brioli A, et al. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients[J]. Blood Cancer J, 2014,4(3):e191.
doi: 10.1038/bcj.2014.13 URL |
| [14] |
Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1[J]. Blood, 2007,109(6):2276-2284.
doi: 10.1182/blood-2006-07-038430 pmid: 17105813 |
| [15] |
Dickens NJ, Walker BA, Leone PE, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome[J]. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64.
doi: 10.1158/1078-0432.CCR-09-2831 URL |
| [16] |
Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials[J]. J Clin Oncol, 2017,35(25):2900-2910.
doi: 10.1200/JCO.2016.69.2517 URL |
| [17] | Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J]. Lancet Oncol, 2016,17(8):e328-e346. |
| [18] | National Comprehensive Cancer Network.Multiple Myeloma (verson 2.2020). |
| [19] | Paiva B, Vidriales MB, Cerveró J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation[J]. Blood, 2008,112(10):4017-4023. |
| [20] |
Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma[J]. Blood, 2015,125(20):3059-3068.
doi: 10.1182/blood-2014-11-568907 URL |
| [21] |
Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry[J]. Leukemia, 2014,28(2):391-397.
doi: 10.1038/leu.2013.217 pmid: 23860448 |
| [22] |
Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123(20):3073-3079.
doi: 10.1182/blood-2014-01-550020 pmid: 24646471 |
| [23] |
Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma[J]. J Clin Oncol, 2015,33(33):3911-3920.
doi: 10.1200/JCO.2014.59.1503 pmid: 26282654 |
| [24] | Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014,6(224):224ra24. |
| [25] |
Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma[J]. Leukemia, 2013,27(3):680-685.
doi: 10.1038/leu.2012.237 pmid: 22902364 |
| [26] |
Gonsalves WI, Rajkumar SV, Gupta V, et al. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma[J]. Leukemia, 2014,28(10):2060-2065.
doi: 10.1038/leu.2014.98 pmid: 24618735 |
| [27] |
Paiva B, Puig N, Cedena MT, et al. Differentiation stage of myeloma plasma cells: biological and clinical significance[J]. Leukemia, 2017,31(2):382-392.
doi: 10.1038/leu.2016.211 pmid: 27479184 |
| [28] |
Peceliunas V, Janiulioniene A, Matuzeviciene R, et al. Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma[J]. Leuk Lymphoma, 2012, 53(4):641-647.
doi: 10.3109/10428194.2011.627481 URL |
| [29] |
Kis O, Kaedbey R, Chow S, et al. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates[J]. Nat Commun, 2017,8:15086.
doi: 10.1038/ncomms15086 URL |
| [30] |
Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma[J]. Leukemia, 2017,31(8):1695-1705.
doi: 10.1038/leu.2016.366 pmid: 27899805 |
| [1] | . [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 551-554. |
| [2] | ZHOU Sifeng, XU Haishu, FAN Xinsheng. Application of metabolomics of different biological samples in study of OSAHS biomarkers [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 535-540. |
| [3] | XIONG Xinhai, LI Jia, DING Xiaosong, JI Congcong, SHI Hourong, XIANG Minjie. Leishmaniasis with secondary hemophagocytic syndrome: a case report [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 524-526. |
| [4] | BAO Zhiyao, MENG Wenkai, SHEN Jimin, LI Qingyun. Hematogenous disseminated pneumonia secondary to suppurative tonsillitis in adults: a case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(04): 520-523. |
| [5] | LI Lei, YUAN Fei, WANG Chaofu, XU Haimin, WANG Ting. Ampullary adenocarcinoma: analysis of the clinicopathological features and prognostic factors [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 355-361. |
| [6] | GUO Yebing, ZHENG Jinfeng. The extra-gastrointestinal stromal tumors located in vagina: A case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 405-407. |
| [7] | . [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 102-104. |
| [8] | HUANG Pei, REN Rujing, PAN Yu, LIN Guozhen, WANG Gang. Early-onset Alzheimer′s disease complicated with cerebral amyloid angiopathy: A case report [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 86-89. |
| [9] | . [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 99-101. |
| [10] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 529-532. |
| [11] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 582-583. |
| [12] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 584-587. |
| [13] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 588-591. |
| [14] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 596-598. |
| [15] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 512-514. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
